Vasina, Daria V. http://orcid.org/0000-0003-1965-0700
Antonova, Nataliia P.
Gushchin, Vladimir A.
Aleshkin, Andrey V.
Fursov, Mikhail V.
Fursova, Anastasiia D.
Gancheva, Petya G.
Grigoriev, Igor V.
Grinkevich, Pavel
Kondratev, Alexey V.
Kostarnoy, Alexey V.
Lendel, Anastasiya M.
Makarov, Valentine V.
Nikiforova, Maria A.
Pochtovyi, Andrei A.
Prudnikova, Tatiana
Remizov, Timofey A.
Shevlyagina, Natalia V.
Siniavin, Andrei E.
Smirnova, Nina S.
Terechov, Alexander A.
Tkachuk, Artem P.
Usachev, Evgeny V.
Vorobev, Aleksei M.
Yakimakha, Victoria S.
Yudin, Sergey M.
Zackharova, Anastasia A.
Zhukhovitsky, Vladimir G.
Logunov, Denis Y.
Gintsburg, Alexander L.
Funding for this research was provided by:
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency (Contract no. 0373100122120000008 of 08 April 2020, no. 0373100122119000013 of 15 May 2019)
Article History
Received: 7 March 2024
Accepted: 8 July 2024
First Online: 24 July 2024
Declarations
:
: All animal procedures were conducted in accordance with the relevant guidelines for the care and use of laboratory animals and approved by the Ethics Committees of the State Research Center for Applied Microbiology and Biotechnology (Protocol number VP-2020/16, 28.10.2020) and N.F. Gamaleya National Research Centre for Epidemiology and Microbiology (Protocol number 28, 05.07.2022).
: Not applicable.
: VDV, NPA, EVU, AMV, AVA, VVM, APT, SMY, and VAG are listed as the inventors in patents (National Registration no. 2021128274 and RU 2781050 C1) related to LysECD7-SMAP dosage forms. VVM and SMY are the current employees of Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency. All other authors declare no competing interests.